# A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)

> **NCT03577171** · PHASE2 · COMPLETED · sponsor: **Assembly Biosciences** · enrollment: 25 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** ABI-H0731
- **DRUG:** SOC ETV
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03577171
- **Lead sponsor:** Assembly Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-19
- **Primary completion:** 2019-06-21
- **Final completion:** 2019-06-21
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03577171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03577171, "A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03577171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*